ABOS - Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc Logo

ABOS - Acumen Pharmaceuticals Inc

https://acumenpharm.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.

52W High
$3.36
52W Low
$0.86
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.14
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.60
EV/Revenue (<3 favorable)
89.67
P/S (TTM) (<3 favorable)
538.78
P/B (<3 favorable)
0.70
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
11.46%
Institutions (25–75% balanced)
67.88%
Shares Outstanding
60,573,000
Float
32,929,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
329,000
Gross Profit (TTM)
-124,207,000
EPS (TTM)
-2.27
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.76%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0070
Previous
0.0013
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025